Novo Nordisk to present data from STEP UP trial on a higher dose of Wegovy ® (semaglutide 7.2 mg) for those in need of greater weight loss Data will expand semaglutide evidence in both a clinical and ...

Wider use of continuous glucose monitoring (CGM), glycemic management during cancer treatment, and individualized dosing of obesity drugs in people with diabetes are just a few of the new topics and ...

IBM Watson and the American Diabetes Association (ADA) will collaborate to create better disease management tools for those affected by diabetes. The project, unveiled at the ADA’s 76 th Scientific ...

Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSema ...